Search
Atabecestat
go.drugbank.com/drugs/DB15307InvestigationalAtabecestat is under investigation in clinical trial NCT02211079 (A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9,
ABP-700
go.drugbank.com/drugs/DB15411InvestigationalABP-700 is under investigation in clinical trial NCT02800590 (Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing Colonoscopy
S-777469
go.drugbank.com/drugs/DB16321InvestigationalS-777469 is under investigation in clinical trial NCT00703573 (A Randomized, Double-blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis).
QXL138AM
go.drugbank.com/drugs/DB18552InvestigationalQXL138AM is a masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a. It binds the CD138 protein on the surface of the tumour cells.
Synonyms: Masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2aSapablursen
go.drugbank.com/drugs/DB18608InvestigationalSapablursen is a synthetic 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a tri-antennary cluster of N-acetyl galactosamine (GalNAc3) sugars targeting transmembrane protease, serine
Bremzalerbart
go.drugbank.com/drugs/DB19417InvestigationalBremzalerbart is under investigation in clinical trial NCT06602739 (A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen
Atisnolerbart
go.drugbank.com/drugs/DB19418InvestigationalAtisnolerbart is under investigation in clinical trial NCT06602739 (A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen
Harmaline
go.drugbank.com/drugs/DB13875ExperimentalCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeNLX-P101
go.drugbank.com/drugs/DB05924ExperimentalNLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. … NLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinson’s patients.
ATN-161
go.drugbank.com/drugs/DB05491Investigationalextend to a variety of cancers. … expression of alpha(5)beta(1) integrin by cancer cells and the role of this molecule in tumor angiogenesis is similar across a range of different cancers, the therapeutic benefit of ATN-161 is expected to